All results reported are for continuing operations, unless otherwise noted. Record quarterly revenue of $82.2 million, representing an increase of 34% year-over-yearQuarterly gross margin of 79.4% and an increase in gross profit of 34% year-over-yearActive Buyers of 1.57 million, representing growth of 26% year-over-year, with new buyer growth of 54% year-over-year, reflecting ThredUp’s best quarter for new buyer acquisition in its historyEnded the quarter with cash and cash equivalents, restricted cash, an ...

Cambridge, Massachusetts, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, and members of senior management will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference on Monday, Nove ...

– Total net sales of $138.5 million, compared to $149.7 million in prior year third quarter –– Net income of $2.7 million, compared to $5.4 million in prior year third quarter –– EBITDA of $7.5 million, compared to $11.7 million in prior year third quarter –– Board of Directors approves $0.14 per share quarterly dividend – ST. PETERSBURG, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”), today announced its third quarter 2025 results. “Our earnings we ...

Nyxoah to Participate in the Stifel 2025 Healthcare Conference Mont-Saint-Guibert, Belgium – November 3, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Stifel 2025 Healthcare Conference on Tuesday, Nov. 11, 2025. The Company is scheduled to present at 9:20am Eastern Time the same day via webcast. A live webcast of th ...

核心观点 - 公司公布2025年第三季度及前九个月强劲财务业绩，营收、利润均实现显著增长，并上调全年业绩指引，同时宣布新的股票回购计划，显示出管理层对业务前景的信心 [1][3][9][14][15] 第三季度财务业绩 - 2025年第三季度总营收为8580万美元，较2024年同期的7310万美元增长1270万美元，增幅达17% [4] - 营收增长主要得益于淋巴水肿产品线销售和租赁收入增加710万美元（增幅11%），以及气道清除产品线销售额增加560万美元（增幅71%） [4] - 毛利润为6500万美元，较2024年同期的5480万美元增长1020万美元，增幅19%；毛利率为76%，高于2024年同期的75% [5] - 营业费用为5400万美元，较2024年同期的4800万美元增长600万美元，增幅13% [5] - 营业利润为1100万美元，较2024年同期的680万美元大幅增长 [5] - 净利润为820万美元，摊薄后每股收益为0.36美元，较2024年同期的520万美元净利润（每股0.21美元）显著提升 [6] - 调整后税息折旧及摊销前利润为1440万美元，较2024年同期的1070万美元增长 [7] 前九个月财务业绩 - 2025年前九个月总营收为2.259亿美元，较2024年同期的2.074亿美元增长1850万美元，增幅9% [10] - 营收增长主要源于气道清除产品线销售额增加1190万美元（增幅47%），以及淋巴水肿产品线销售和租赁收入增加660万美元（增幅4%） [10] - 净利润为850万美元，摊薄后每股收益为0.36美元，高于2024年同期的720万美元净利润（每股0.30美元） [11] - 调整后税息折旧及摊销前利润为2180万美元，较2024年同期的2080万美元有所增长 [12] 业务亮点与战略进展 - 公司在淋巴水肿治疗领域取得进展，公布了Flexitouch® Plus作为头颈癌患者淋巴水肿一线疗法可持续益处的六个月数据 [9] - 公司于2025年7月31日偿还了2400万美元定期贷款的全部未偿还本金，并对其循环信贷设施进行再融资，将额度从2500万美元提高至4000万美元 [13] - 公司宣布董事会授权一项新的股票回购计划，可在2027年11月3日前回购最多2500万美元普通股 [14] 资产负债表与现金流 - 截至2025年9月30日，公司现金余额为6600万美元，无未偿还借款；相比之下，2024年12月31日现金余额为9440万美元，未偿还借款为2630万美元 [13] - 2025年前九个月经营活动产生的净现金为2550万美元 [32] 2025年财务展望 - 公司上调2025年全年业绩指引，目前预计总营收在3.17亿美元至3.21亿美元之间，同比增长约8%至10%，此前指引为3.10亿美元至3.15亿美元 [15] - 公司目前预计2025年全年调整后税息折旧及摊销前利润在3800万美元至3950万美元之间，高于此前3300万美元至3500万美元的指引区间，也高于2024年全年的3710万美元 [16][38]

TORONTO and HAIFA, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) announced today that it has been accepted to the BioFab Startup Lab, part of the Advanced Regenerative Manufacturing Institute (ARMI) and its BioFabUSA program. The federally-supported program, launched through a grant from the U.S. Economic Development Administration, helps early-stage biotechnology companies accelerate the translation of regenerative innov ...

Navitas 2.0 - strategic pivot to high-power markets with GaN and high-voltage SiCKey market focus on AI data center, performance computing, energy & grid infrastructure and industrial electrificationDecisive actions and reallocation of resources to those high-growth, higher-margin markets TORRANCE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS), the industry leader in next-generation GaNFast™ gallium nitride (GaN) and GeneSiC™ high-voltage silicon carbide (SiC) power semicond ...

MIDLAND, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ:VNOM) (“Viper,” “we,” “our” or the “Company”), a subsidiary of Diamondback Energy, Inc. (NASDAQ:FANG) (“Diamondback”), today announced financial and operating results for the third quarter ended September 30, 2025. THIRD QUARTER HIGHLIGHTS Q3 2025 average production of 56,087 bo/d (108,859 boe/d)Q3 2025 consolidated net loss (including non-controlling interest) of $197 million; net loss attributable to Viper of $77 million, or $0.5 ...

All financial figures are in Canadian dollars unless otherwise noted CALGARY, Alberta, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Gibson Energy Inc. (TSX:GEI) ("Gibson" or the "Company") announced today its financial and operating results for the three and nine months ended September 30, 2025. Key Highlights: Delivered Infrastructure Adjusted EBITDA(1) of $154 million, driven by strong volume growthCanadian record of 1.5 mmbbl per day, a 26% increase year-over-year, led by Hardisty and TMX-connected tanks at Edmonto ...

DALLAS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” “CSWC” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, today announced its financial results for the second fiscal quarter ended September 30, 2025. Second Quarter Fiscal Year 2026 Financial Highlights Total Investment Portfolio: $1.9 billion Credit Portfolio of $ ...